



20 April 2016

ASX ANNOUNCEMENT

APPENDIX 4C – Quarter Ended 31 March 2016

Brisbane, Australia - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, today released its Appendix 4C – Quarterly cash flow report for the period ended 31 March 2016.

Total revenue for the quarter was \$1.5 million, including lymphoedema sales of \$0.9 million. Operating cash outflow for the quarter was \$6.5 million. Cash receipts from customers for the quarter were \$1.3 million and cash on hand as of 31 March 2016 was \$86.1 million.

Highlights for the past quarter include:

- Signed and trained 17 new accounts of the 50 targeted for CY2016 in the first quarter since commercial launch; integration into electronic health records at these centres now underway;
- Closed successful private placement of \$75 million;
- Medical Advisory Board for Chronic Heart Failure (CHF) established and now finalising study design for CHF;
- New website, social media and PR campaign launched in the US, driving increased awareness of ImpediMed's suite of lymphoedema, body composition and fluid status technologies;
- Increased investment in expanded sales and marketing team
- Accelerated development of next generation device for in-clinic and at-home settings;
- Ms Elizabeth Gaines appointed to the Board of Directors as a Non-Executive Director and Chairman of the Audit and Risk Committee.

“This has been an extremely busy quarter and we have made progress on many fronts. Since the full US commercial launch commenced, we have experienced an increased rate of adoption of our L-Dex technology with 17 new centres now signed with training complete, patient care pathways established and integration into electronic health records underway, putting us ahead of schedule as we target 50 of the top 500 cancer centers this year and laying the foundation for increased revenue flow.”

“The completion of our \$75 million placement is an important milestone which significantly strengthens our balance sheet and which has enabled us to expedite our planning for our second indication, chronic heart failure (CHF), as well as accelerate the development of our next generation device which will be suitable for use in the clinic and at home, lymphoedema, body composition, and CHF,” stated Managing Director and CEO, Richard Carreon.

For personal use only

Investor Conference Call

An investor conference call hosted by Managing Director and CEO, Richard Carreon will be held on: **Thursday 21st April at 9.00am AEST.**

Conference ID: 455644

Pre-register at <https://www.choruscallaustralia.com.au/DiamondPass/ImpediMed-455644-DiamondPassInvite.html> to avoid a queue when dialing in. Upon registration you will receive a calendar reminder and unique pin for express entry into the conference call.

If you cannot pre-register, please dial any of the numbers below at the conference call start time and quote the conference ID provided above.

Australia	1800 908 299 or +61 2 9007 8048
US/Canada	1855 624 0077
UK	0800 051 1453
Singapore	800 101 2702
Hong Kong	800 968 273
New Zealand	0800 452 795
Japan	0066 3386 8000

- ENDS -

Richard Carreon
Managing Director & CEO

For further information, contact:
Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.

For personal use only

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

ImpediMed Limited

ABN

65 089 705 144

Quarter ended ("current quarter")

31 March 2016

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter	Year to date (nine months)
	\$A'000	\$A'000
1.1 Receipts from customers	1,309	4,172
1.2 Payments for		
(a) staff costs	(3,617)	(10,004)
(b) advertising and marketing	(305)	(650)
(c) research and development	(1,257)	(2,141)
(d) leased assets	(6)	(18)
(e) other working capital	(2,608)	(7,006)
1.3 Dividends received	0	0
1.4 Interest and other items of a similar nature received	10	38
1.5 Interest and other costs of finance paid	0	0
1.6 Income taxes paid	0	0
1.7 Other (provide details if material)	0	0
Net operating cash flows	(6,474)	(15,609)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (nine months) \$A'000
1.8 Net operating cash flows (carried forward)	(6,474)	(15,609)
1.9 Cash flows related to investing activities		
Payment for acquisition of:		
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	(22)	(54)
(e) other non-current assets	0	0
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	0	0
(e) other non-current assets	0	0
1.11 Loans to other entities	0	0
1.12 Loans repaid by other entities	0	0
1.13 Other (provide details if material)	0	0
Net investing cash flows	(22)	(54)
1.14 Total operating and investing cash flows	(6,496)	(15,663)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	71,155	71,405
1.16 Release of restricted cash	0	0
1.17 Proceeds from borrowings	0	0
1.18 Repayment of borrowings	0	0
1.19 Dividends paid	0	0
1.20 Other (provide details if material)	0	0
Net financing cash flows	71,155	71,405
Net increase (decrease) in cash held	64,659	55,742
1.21 Cash at beginning of quarter/year to date	25,152	32,582
1.22 Exchange rate adjustments to item 1.20	(3,705)	(2,218)
1.23 Cash at end of quarter	86,106	86,106

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	121
1.25	Aggregate amount of loans to the parties included in item 1.11	0

1.26 Explanation necessary for an understanding of the transactions

Item 1.24: Payments to directors consist of Directors' salaries and superannuation and Directors' fees for the quarter and year-to-date. These figures include only Non-Executive Directors and exclude Directors' salaries and Directors' fees that were accrued and unpaid as at the end of the quarter. At 31 March 2016 there were \$50,000 fees accrued and unpaid.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	---	---
3.2	Credit standby arrangements	---	---

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	7,859	25,152
4.2 Deposits at call	78,247	0
4.3 Bank overdraft	0	0
4.4 Other (provide details)	0	0
Total: cash at end of quarter (item 1.23)	86,106	25,152

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration	N/A	N/A
5.3 Consideration for acquisition or disposal	N/A	N/A
5.4 Total net assets	N/A	N/A
5.5 Nature of business	N/A	N/A

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:



Date:

20 April 2016

Print name: Morten Vigeland
Chief Financial Officer

+ See chapter 19 for defined terms.

For personal use only

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.